Primary Immunodeficiency Drug Pipeline: 24 Assets by Phase

How many primary immunodeficiency drugs are in each phase of development?

Douglas Insights counts 16 primary immunodeficiency candidates in Phase III, 67% of the 24 assets in development; Phase II holds 4 and Phase I holds 4.

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each primary immunodeficiency asset appears in exactly one row. The 70 trials still recruiting or running carry 43% of the 161 registered trials in scope.

Which approved primary immunodeficiency medicines are still in trials?

5 medicines already on the market are still being tested in primary immunodeficiency Phase IV trials; KVD900 has the most, with 7 registered trials.

Post-approval primary immunodeficiency trials test new doses, new patient groups and head-to-head comparisons. They set the standard of care that every candidate in development will be measured against, so the paid review profiles each one.

How many primary immunodeficiency trials are recruiting patients now?

27 primary immunodeficiency trials are recruiting patients and 7 more have not started recruiting yet, out of 161 interventional trials in scope; together they make up 21% of the trial base.

Terminated, suspended and withdrawn primary immunodeficiency trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the primary immunodeficiency pipeline?

Bellicum Pharmaceuticals leads the primary immunodeficiency pipeline with 2 candidates; the top 5 sponsors hold 33% of the 24 assets, and 21 sponsors run at least one.

Industry sponsors lead 97 of the 161 primary immunodeficiency trials (60%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the primary immunodeficiency pipeline?

Mechanism and drug-type classification for the 24 primary immunodeficiency candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What primary immunodeficiency trial readouts are coming next?

8 primary immunodeficiency candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many primary immunodeficiency readouts fall in each quarter?

13 primary immunodeficiency candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 6, due in Q4 2026.

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most primary immunodeficiency trials?

United States hosts the most primary immunodeficiency trials, with sites in 115 of the 161 studies (71%); trials in scope run in 48 countries in all.

A multinational primary immunodeficiency trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are primary immunodeficiency drugs being tested?

115 of the 161 primary immunodeficiency trials (71%) have a site in the United States, 69 (43%) in Europe and 8 (5.0%) in China; 18 of the 24 candidates in development are tested in the US.

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational primary immunodeficiency trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the primary immunodeficiency pipeline since the last update?

This is the first edition of the primary immunodeficiency pipeline count, dated 4 Oct 2026. The next refresh is due by 2 Jan 2027, and each refresh lists the assets that entered, advanced or dropped out.

How does Douglas Insights count the primary immunodeficiency pipeline?

Douglas Insights read 161 interventional trials registered on ClinicalTrials.gov for the conditions "Primary Immunodeficiency Diseases", "primary immunodeficiency" and updated since 4 Oct 2021, then grouped every drug or biologic named in them into 24 unique candidates.

1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

Frequently asked questions about the primary immunodeficiency pipeline

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Adjacent coverage